- Home
- AKRO vs LAZ Comparison
AKRO vs LAZ Comparison
Compare AKRO & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- LAZ
- Stock Information
- Founded
- AKRO 2017
- LAZ 1848
- Country
- AKRO United States
- LAZ United States
- Employees
- AKRO N/A
- LAZ N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- LAZ Investment Managers
- Sector
- AKRO Health Care
- LAZ Finance
- Exchange
- AKRO Nasdaq
- LAZ Nasdaq
- Market Cap
- AKRO 3.9B
- LAZ 4.1B
- IPO Year
- AKRO 2019
- LAZ 2005
- Fundamental
- Price
- AKRO $54.20
- LAZ $43.66
- Analyst Decision
- AKRO Strong Buy
- LAZ Hold
- Analyst Count
- AKRO 6
- LAZ 7
- Target Price
- AKRO $82.50
- LAZ $44.33
- AVG Volume (30 Days)
- AKRO 1.8M
- LAZ 777.5K
- Earning Date
- AKRO 08-08-2025
- LAZ 07-24-2025
- Dividend Yield
- AKRO N/A
- LAZ 4.58%
- EPS Growth
- AKRO N/A
- LAZ N/A
- EPS
- AKRO N/A
- LAZ 2.87
- Revenue
- AKRO N/A
- LAZ $2,939,019,000.00
- Revenue This Year
- AKRO N/A
- LAZ N/A
- Revenue Next Year
- AKRO N/A
- LAZ $14.45
- P/E Ratio
- AKRO N/A
- LAZ $15.19
- Revenue Growth
- AKRO N/A
- LAZ 7.18
- 52 Week Low
- AKRO $21.02
- LAZ $31.97
- 52 Week High
- AKRO $58.40
- LAZ $61.14
- Technical
- Relative Strength Index (RSI)
- AKRO 62.96
- LAZ 51.28
- Support Level
- AKRO $53.61
- LAZ $42.88
- Resistance Level
- AKRO $56.49
- LAZ $44.27
- Average True Range (ATR)
- AKRO 2.40
- LAZ 1.20
- MACD
- AKRO -0.08
- LAZ -0.14
- Stochastic Oscillator
- AKRO 65.93
- LAZ 43.30
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.